This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=106 http://www.lsis.com/goto/r106/rss 2012-02-05T11:11:07+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Obesity and obesity-related metabolic diseases represent a growing socioeconomic problem throughout the world. Great emphasis has been put on establishing treatments for this condition, including pharmacological intervention. However, there are many obstacles and pitfalls in the development process from pre-clinical research to the pharmacy counter, and there is no certainty that what has been observed pre-clinically will translate into an improvement in human health. Hence, it is important to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 The effect of 'typical' and 'atypical' neuroleptics on interstitial levels of the dopamine metabolite 3,4- dihydroxyphenylacetic acid ([DOPAC]e) in the dorsolateral striatum (DLSt), the nucleus accumbens (NAc) and the medial prefrontal cortex (PFC) was investigated in awake rats by use of the microdialysis technique. All neuroleptics increased [DOPAC]e in the DLSt, NAc and in PFC. However, the 'atypical' neuroleptics clozapine, risperidone, sertindole and NNC 22-0031 showed an apparent (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 BACKGROUND: Diabetes status is an independent marker of restenosis after percutaneous coronary intervention (PCI). Previous studies suggest that metabolic abnormalities associated with diabetes increase stent restenosis by promoting intimal hyperplasia. Preclinical studies have indicated that insulin therapy reduces intimal hyperplasia. The objective of this study was to determine whether insulin-mediated glucose lowering reduces in-stent restenosis in patients with diabetes undergoing PCIs. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - February 03, 2012) - Company Announcement no 8 2012: http:/hugin.info/2013/R/1582573/494506.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - February 02, 2012) - Sales growth of 9% driven by Victoza, NovoRapid and Levemir Company Announcement no 7 / 2012: http:/hugin.info/2013/R/1581997/494216.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 J Psychopharmacol. |-| Jackson HC. |-| Pharmaceutical Research Division Novo Nordisk A/S Novo Nordisk Park Mløv, Denmark. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 J Psychopharmacol. |-| Jackson HC. |-| Pharmaceutical Research Division, Novo Nordisk A/S, Novo Nordisk Park, Mløv, Denmark. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 J Psychopharmacol. |-| Nielsen EB, Andersen PH. |-| Departments of CNS Pharmacology and Biochemical Pharmacology, CNS Division, Novo Nordisk A/S, DK-2880 Bagsuaerd, Denmark. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Aims:? The aim of this study was to investigate the vascular effects of liraglutide in patients well controlled on metformin monotherapy. Methods:? Forty-four patients with Type?2 diabetes were included in the study. Main inclusion criteria were: pretreatment with metformin on a stable dosage, HbA(1c) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 AIMS/HYPOTHESIS: The aim of this study was to evaluate the separate impact of insulin resistance and impaired glucose tolerance (IGT) on the incretin effect. METHODS: Twenty-one healthy glucose-tolerant first-degree relatives of patients with type 2 diabetes underwent a 75 g OGTT, an isoglycaemic i.v. glucose test and a mixed meal to evaluate the incretin effect before and after treatment with dexamethasone to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Of the mammalian species, only the GLP-1 receptors of rat and human origin have been described and characterized. Here, we report the cloning of the homologous GLP-1 receptors from mouse, rabbit, pig, cynomolgus monkey and chimp. The GLP-1 receptor is highly conserved across species, thus underlining the physiological importance of the peptide hormone and its receptor across a wide range of mammals. We expressed the receptors by stable transfection of BHK cells, both in cell lines with high (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Small synthetic ligands for protein purification have become increasingly interesting with the growing need for cheap chromatographic materials for protein purification and especially for the purification of monoclonal antibodies (mAbs). Today, Protein A-based chromatographic resins are the most commonly used capture step in mAb down stream processing; however, the use of Protein A chromatography is less attractive due to toxic ligand leakage as well as high cost. Whether used as an (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 SAN DIEGO (January 23, 2012) La Jolla Institute scientist Matthias von Herrath, M.D., a world leader in basic research on type 1 diabetes, has long dreamed of seeing his discoveries translated into new therapies to better treat this serious and chronic disorder. Dr. von Herrath may soon get his chance as head of a new translational type 1 diabetes center to be opened in Seattle in 2012 by Novo Nordisk, a global healthcare company specializing in diabetes care. Dr. von Herrath will continue to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - January 23, 2012) - On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Company Announcement no 5 2012: http:/hugin.info/2013/R/1579436/492853.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 Drug giant Novo Nordisk has nabbed Paula Deen, the celebrity chef who popularized, among other things, cheeseburger meatloaf and hamburgers served with eggs and bacon on doughnuts instead of buns, as a new spokeswoman to help raise awareness about type 2 diabetes which she has. Many in the drug industry wish it weren t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east. That s too bad, because it may not (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8096978 |-| Title: Automatic injection device with a top release mechanism |-| Inventors: Markussen; Tom Hede (Bagsv.ae butted.rd, DK) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8097584 |-| Title: Stabilized formulations of insulin that comprise ethylenediamine |-| Inventors: Poulsen; Christian (Copenhagen K, DK) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| The present invention relates to a pharmaceutical formulation comprising insulin, an insulin analogue or an insulin derivate and ethylenediamine or salts thereof and an antimicrobial preservative agent. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8097698 |-| Title: Derivatives of GLP-1 analogs |-| Inventors: Knudsen; Liselotte Bjerre (Valby, DK), Huusfeldt; Per Olaf (Copenhagen O, DK), Nielsen; Per Franklin (Vaerlose, DK), Kaarsholm; Niels C. (Vanlose, DK), Olsen; Helle Birk (Allerod, DK), Bjorn; Soren Erik (Lyngby, DK), Pedersen; Freddy Zimmerdahl (Vaerlose, DK), Madsen; Kjeld (Vaerlose, DK) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| The present invention relates to a pharmaceutical composition comprising (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 BACKGROUND: Thinner and shorter needles for subcutaneous administration are continuously developed. Previous studies have shown that a thinner needle causes fewer occurrences of painful needle insertions and that a shorter needle decreases the occurrence of painful intramuscular injections. However, little is known about local drug delivery in relation to needle length and thickness. This study aimed to compare deposition depth and backflow from three hypodermic needles of 3 mm 34G (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Mdc1 is a large modular phosphoprotein scaffold that maintains signaling and repair complexes at double-stranded DNA break sites. Mdc1 is anchored to damaged chromatin through interaction of its C-terminal BRCT-repeat domain with the tail of ?H2AX following DNA damage, but the role of the N-terminal forkhead-associated (FHA) domain remains unclear. We show that a major binding target of the Mdc1 FHA domain is a previously unidentified DNA damage and ATM-dependent phosphorylation site near the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Liraglutide and exenatide are glucagon-like peptide receptor (GLP-1R) agonists used in the treatment of type 2 diabetes. Both molecules have been associated with the development of thyroid C-cell tumors after lifetime exposure in rodents. Previously, it has been reported that these tumors are preceded by increased plasma calcitonin and C-cell hyperplasia. We can now document that the murine C-cell effects are mediated via GLP-1R. Thus, 13 wk of continuous exposure to GLP-1R agonists was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 AIMS/HYPOTHESIS: A positive impact of exercise intervention programmes on quality of life (QoL) may be important for long-term patient compliance to exercise recommendations. We have previously shown that QoL improves significantly with supervised exercise, whereas it worsens with counselling alone, in patients with type 2 diabetes from the Italian Diabetes and Exercise Study (IDES). Here, we report data on the relationship between changes in QoL and volume of physical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 In periodontitis, an effective host-response is primarily related to neutrophils loaded with serine proteases, including elastase (NE) and protease 3 (PR3), the extracellular activity of which is tightly controlled by endogenous inhibitors. In vitro these inhibitors are degraded by gingipains, cysteine proteases produced by Porphyromonas gingivalis. The purpose of this study was to determine the level of selected protease inhibitors in gingival crevicular fluid (GCF) in relation to periodontal (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 FloSeal (hemostatic gelatin matrix with a human-derived thrombin component; Baxter Healthcare, Deerfield, IL, USA) hemostatic matrix is used as an adjunct to hemostasis when conventional procedures have proved ineffective. In the present case, FloSeal was used in combination with transfusions, NovoSeven (recombinant activated human factor VIIa; Novo Nordisk, Copenhagen, Denmark) and compression to achieve hemostasis in a patient with postpartum bleeding and hypofibrinogenemia due to primary (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Aim: Previous studies with the novel once-daily GLP-1 analog liraglutide and the GLP-1 receptor agonist exenatide have revealed profound insulinotrophic and anti-diabetic effects, but also potent effects on gastric emptying and long-term and lasting reductions in body-weight. In the current study we examined the acute and chronic effects of two different GLP-1 analogs with different pharmacokinetic profiles on gastric emptying, food intake and body-weight. Methods: Based on a series of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - January 09, 2012) - On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 2 November 2011 to 31 January 2012. Company Announcement no 3 2012: (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 The 29-residue peptide hormone glucagon forms many different morphological types of amyloid-like fibrils, depending on solvent conditions. Here, we combine time-series far-UV circular dichroism with singular value decomposition (SVD) analysis to reveal six different conformational states populated during fibrillation at 25°C and pH 2.5. The existence of these states is supported by complementary fluorescence and electron microscopy data. This highlights a multitude of structural transitions (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8088731 |-| Title: Use of GLP-1 compound for treatment of critically ill patients |-| Inventors: Knudsen; Lotte Bjerre (Valby, DK), Selmer; Johan (Farum, DK), Hansen; Kristian Tage (Slangerup, DK) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| Use of medicament for life saving treatment of critically ill patients and method of treatment. The medicament comprises a GLP-1 compound which effectively controls the blood glucose level. text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - January 02, 2012) - Company Announcement no 2 / 2012: http:/hugin.info/2013/R/1574580/490192.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 AIMS/HYPOTHESIS: Endothelial dysfunction is important in the development of vascular complications in diabetes. Patients with type 2 diabetes have increased production of the vasoconstrictor and pro-inflammatory peptide, endothelin-1. Short-term intra-arterial administration of endothelin antagonists improves endothelium-dependent vasodilatation in patients with type 2 diabetes. We tested the hypothesis that oral administration of the dual endothelin receptor antagonist, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - December 27, 2011) - On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Compnay Announcement no 81 2011: http:/hugin.info/2013/R/1573933/489957.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Diabetes mellitus is a highly prevalent condition in patients participating in cardiopulmonary rehabilitation. However, research and subsequent guidelines specifically applicable to patients with diabetes, participating in cardiopulmonary rehabilitation, are limited. Recognizing this limitation, the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) initiated this statement, with the goal of developing a template that incorporated recommendations provided in the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 The epidermal growth factor receptor (EGFR) is an important regulator of normal growth and differentiation, and it is involved in the pathogenesis of many cancers. Endocytic downregulation is central in terminating EGFR signaling after ligand stimulation. It has been shown that also p38 MAPK activation can induce EGFR endocytosis. This endocytosis lacks many of the characteristics of ligand-induced EGFR endocytosis. We compared the two types of endocytosis with regard to the requirements for (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8084053 |-| Title: Dry mouldable drug formulation |-| Inventors: Buch-Rasmussen; Thomas (Gentofte, DK), Flink; James M. (Klampenborg, DK), Poulsen; Jens Ulrich (Virum, DK), Aasmul; Soren (Holte, DK), Hansen; Philip (Holte, DK), Mortensen; Claus Juul (Frederiksberg, DK) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| Solid pharmaceutical compositions and methods of making and administering for parenteral injection comprising a binder and at least one therapeutic agent. (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8083711 |-| Title: Injection device with internal dose indicator |-| Inventors: Enggaard; Christian Peter (Vejby, DK) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| The present invention relates to an injection device comprising a housing, a resilient member adapted to provide a force in the axial direction of the injection device for ejecting a dose from the injection device. The injection device further comprises a dose setting member operatively connected to a dose (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 The aim of this study was to evaluate the weight change from baseline while using insulin detemir in subjects with type 2 diabetes mellitus under normal clinical practice conditions. It was a multicentre, open label, non-randomised, non-interventional, observational, safety and efficacy study in subjects using insulin detemir for the treatment of type 2 diabetes mellitus. In this study, the mean body weight decreased marginally by -0.8 kg at the end of week 26 from baseline. Change in mean (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - December 22, 2011) - Novo Nordisk today announced the submission to the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, of a new drug application for the approval of ultra-long-acting insulin Degludec. This new-generation basal insulin has been developed for the treatment of people with type 1 and type 2 diabetes. Company Announcemen no 80 / 2011: http:/hugin.info/2013/R/1573350/489678.pdf This announcement is distributed by Thomson Reuters on (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - December 19, 2011) - Company Announcement 79 2011: http:/hugin.info/2013/R/1572416/489264.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S via (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Summary.? Patients with congenital haemophilia with inhibitors experience acute bleeds managed with bypassing agents, such as recombinant FVIIa (rFVIIa). Home-based treatment and dosing patterns in the US remain poorly described. This study aimed to assess the prescribed and actual rFVIIa dosing in frequently bleeding inhibitor patients (?4 bleeds in 3?months) prescribed first-line therapy with rFVIIa. Patients or caregivers recorded daily diaries, including the details of all bypassing (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Summary.? General guidelines exist for the use of recombinant activated factor VII (rFVIIa) to maintain haemostasis during surgery in congenital haemophilia A and B patients with high responding inhibitors (CHwI). Individual surgical plans are required and based upon historical therapy response, adverse events and anticipated procedure. Surgical interventions are feasible, yet it remains unclear how many US hemophilia treatment centres (HTCs) perform procedures in this fragile population. To (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Christensen AD, Haase C. Immunological mechanisms of contact hypersensitivity in mice. APMIS 2012; 120: 1-27. Contact hypersensitivity (CHS) is an animal model in which the immunological mechanisms of allergic contact dermatitis (ACD) in humans can be studied but is also widely used in the study of many basic immunological mechanisms. In CHS, a pre-sensitized animal is re-exposed to an antigen, thereby eliciting an immunological reaction at the site of antigen exposure. CHS consists of two (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Among serum proteins albumin and transferrin have attracted the most interest as drug carriers in the past two decades. Prior to that, their potential use was overshadowed by the advent of monoclonal antibodies that was initiated by Milstein and Koehler in 1975. Meanwhile intensive pursuit of exploiting transferrin, but above all albumin as an exogenous or endogenous carrier protein for treating various diseases, primarily cancer, rheumatoid arthritis, diabetes and hepatitis has resulted in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Aims:? The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type?1 diabetes mellitus in a 16-week, open-label, randomizsed trial. Health status, an important aspect of effective diabetes management, was also assessed. Methods:? Degludec (n?=?59) or glargine (n?=?59) were injected once daily, with insulin aspart at mealtimes. Health status assessment utilized the (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8075522 |-| Title: Disposable double pointed injection needle, and an insulin injection system comprising a disposable double pointed injection needle |-| Inventors: Larsen; Carsten Gerner (Kgs. Lyngby, DK), Stenholt; Lars (Humlebaek, DK), Molin; Anders (Kobenhavn K, DK), Rex; Jorn (Roskilde, DK), Larsen; Bjorn Gullak (Bagsvaerd, DK) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| A disposable double pointed injection needle has a needle hub to which a thin needle (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=106 United States Patent: 8076292 |-| Title: Factor VIII: remodeling and glycoconjugation of factor VIII |-| Inventors: DeFrees; Shawn (North Wales, PA), Zopf; David A. (Wayne, PA), Bayer; Robert J. (San Diego, CA), Bowe; Caryn (Doylestown, PA), Hakes; David James (Willow Grove, PA), Chen; Xi (Lansdale, PA) |-| Assignee: Novo Nordisk A/S (Bagsvaerd, DK) |-| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - December 12, 2011) - Company Announcement no 78 / 2011: http:/hugin.info/2013/R/1570658/488426.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - December 08, 2011) - Company Announcement no 77 2011: http:/hugin.info/2013/R/1570118/488162.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=106 Linezolid is an oxazolidinone antibiotic in clinical use for the treatment of serious infections of resistant gram-positive bacteria. It inhibits protein synthesis by binding to the peptidyl transferase center on the ribosome. Almost all known resistance mechanisms involve small alterations to the linezolid binding site, so this review will therefore focus on the various changes that can adversely affect drug binding and confer resistance. High-resolution structures of linezolid bound to the (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=106 ScienceDaily (Dec. 5, 2011) Babies born at a very low birth weight are more likely to have memory and attention problems when they become adults than babies born at a low to normal weight, according to a study published in the December 6, 2011, print issue of Neurology , the medical journal of the American Academy of Neurology. See Also: Health & Medicine Diet and Weight Loss Obesity Infant's Health Mind & Brain Dieting and Weight Control Mental Health Intelligence Reference Birth weight (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=106 BAGSVAERD, DENMARK-(Marketwire - December 05, 2011) - Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 2 November 2011 to 31 January 2012. Company Announcement no 76 / 2011: http:/hugin.info/2013/R/1569088/487688.pdf This (…)